Loading stock…

Liquidia Corporation (LQDA) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Liquidia Corporation

LQDAMarket cap $2.39BPrice $26.7

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops and markets inhaled therapies for rare cardiopulmonary diseases like pulmonary hypertension. Its dry-powder treprostinil formulation lets patients ditch bulky nebulizers, going head-to-head with United Therapeutics in a market worth billions.

In Bastion Portfolios?

52W Return+19%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+115%10

Revenue Forecast

Rev CAGR (1y)+372%10

Rev CAGR (3y)+93%10

Rev CAGR (5y)+60%10

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+11%7

EPS Growth Y+3+38%9

Quality

Margins

EBIT Margin37%9

Net Income Margin31%9

Free Cash Flow Margin33%9

Debt

Net Debt/EBITDA-0.610

Efficiency

ROE132%10

ROA36%10

Earnings Stability22

GEAR+VERY STRONG97

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)510

P/E Ratio (Forward 3y)510

P/BV12.21

EV Multiples

EV/EBITDA Fwd69

EV/EBIT Fwd610

Yield

Free Cash Flow Yield6.3%7

Dividend Yieldna–

Momentum

Short term

1 month return-61%1

3 month return-66%1

YTD return-23%2

Mid term

Price vs 52wHigh29%1

1 year return+11%6

Long term

3 year return+303%10

5 year return+877%10

Risk Shield

Price Risk

Beta1.61

Volatility107%1

Free Cash Flow

Free Cash Flow Margin33%9

Free Cash Flow Yield6.3%7

Quality

ROCE66%10

Earnings Stability22

Net Debt/EBITDA-0.610

02Growth

Is it actually growing, and how fast?

LQDALiquidia

Revenue FY25$158M

GROWTH RATING↗

VERY STRONG97 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+115%10

Revenue, next 1Y+372%10

Revenue, next 3Y, CAGR+93%10

Revenue, next 5Y, CAGR+60%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+11%7

EPS growth, FY28E+38%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 97% of companies worldwide.

Revenue grew 115%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 93%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 60%/yr over five years.10/10

WATCH

Revenue grew 115%/yr over the last 3 years; forecasts see it cooling to 93%/yr.

Earnings are set to grow slower than sales (EPS about 11%/yr vs revenue 93%/yr), so margins are under pressure.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK31 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-61%1

3-month return-66%1

YTD return-23%2

MID & LONG-TERM▾SCORE

% of 52-week high29%1

1-year return+11%6

3-year return+303%10

5-year return+877%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +303% over three years and +877% over five, ahead of 90% of the market.

WATCH

None flagged.

WEAKNESSES

It's up 11% over the past year, but 71% below its 52-week high. That is a touch behind the market.

The stock is underperforming over the past month (-61%), over three months (-66%) and so far this year (-23%).

BOTTOM LINE

Outperformer in a Drawdown

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Liquidia Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

LQDALiquidia

Revenue FY25$158M

GROWTH RATING↗

VERY STRONG97 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+115%10

Revenue, next 1Y+372%10

Revenue, next 3Y, CAGR+93%10

Revenue, next 5Y, CAGR+60%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+11%7

EPS growth, FY28E+38%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 97% of companies worldwide.

Revenue grew 115%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 93%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 60%/yr over five years.10/10

WATCH

Revenue grew 115%/yr over the last 3 years; forecasts see it cooling to 93%/yr.

Earnings are set to grow slower than sales (EPS about 11%/yr vs revenue 93%/yr), so margins are under pressure.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK31 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-61%1

3-month return-66%1

YTD return-23%2

MID & LONG-TERM▾SCORE

% of 52-week high29%1

1-year return+11%6

3-year return+303%10

5-year return+877%10

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +303% over three years and +877% over five, ahead of 90% of the market.

WATCH

None flagged.

WEAKNESSES

It's up 11% over the past year, but 71% below its 52-week high. That is a touch behind the market.

The stock is underperforming over the past month (-61%), over three months (-66%) and so far this year (-23%).

BOTTOM LINE

Outperformer in a Drawdown

04Value

Are you paying a fair price for it?

Stop guessing on Liquidia Corporation. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community